List
The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until April, 2020.
-
IGF OT IGF FY IWIN NAVIGATING YOUR PATH TO WELL BEING SBIR PHASE II BASE AWARD PERIOD OF PERFORMANCE
SBC: Pro-Change Behavior Systems Inc Topic: NIDANot Available
SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
Virus specific diagnosis of hepatitis infection using isothermal amplification in resource poor settings
SBC: Carrera Bioscience Inc. Topic: ODCDCThere is a pressing need to detect and differentiate all forms of viral hepatitis in patient samples as a point of care assay The existing FDA cleared PCR based HBV and HCV diagnosis kits require sophisticated instrument and sample processing which is not applicable for field use Carrera Bioscience proposes to develop assays for all five hepatitis viruses using loop mediated isothermal ampl ...
SBIR Phase I 2015 Department of Health and Human Services -
A Novel Approach to Purifying iPSC Derived Cell Cultures
SBC: HocusLocus Inc. Topic: 200DESCRIPTION provided by applicant We are pioneering an RNA based switch technology called structurally interacting RNAs sxRNA which utilizes post transcriptional gene regulation as a reporter for miRNA detection Normally RNA binding proteins RBP associate with a andapos stem loop structure to facilitate translation of an upstream coding region by as much as an order of magnitude It is ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Integrated biochemical and bioinformatic technologies for accurate transcriptome-wide full-length RNA assembly.
SBC: LUCIGEN CORPORATION Topic: 172DESCRIPTION provided by applicant The human transcriptome is significantly more complex than its cognate genome due to the hundreds of thousands of possible isoforms allele specific expression issues variable RNA editing changes and differential expression patterns spanning cell types developmental stages and physiological stresses Next generation sequencing NGS platforms are fundame ...
STTR Phase I 2015 Department of Health and Human Services -
Electronic Optimization of Stem Cell Derived Human Cardiac Myocytes
SBC: Cytocybernetics Inc Topic: NHLBIDESCRIPTION provided by applicant As part of the FDA approval process for novel therapeutic drugs safety screening demonstrating that the new drug does not have deleterious effects on the human cardiac action potential is required Healthy human heart cells are not available for such preclinical drug testing There is currently no consensus on the best experimental approach to provide the most ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Novel Silica-Based Organic Polymer for Ambient Ionization Mass Spectrometry
SBC: Prosolia, Inc. Topic: NIGMSDESCRIPTION provided by applicant Most samples of chemical interest are complex mixtures making the usual combination of chromatography with mass spectrometry MS a natural choice However the increased demand for chemical analysis by mass spectrometry in many areas of science makes it imperative to increase efficiency of analysis by minimizing sample workup and overall analysis time which ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Evaluation of TRB-N0224, a Proprietary Chemically Modified Curcumin, for the Treatment of Periodontal Disease in a LPS-Induced Rat Model
SBC: TRAVERSE BIOSCIENCES, INC. Topic: NIDCRDESCRIPTION provided by applicant Traverse Biosciences Inc is a pre clinical stage drug development company working to commercialize new chemical entities which act to resolve inflammatory conditions through pleiotropic host modulation of pathologically unrestrained matrix metalloproteinases MMPs and pro inflammatory cytokines The companyandapos s lead drug candidate TRB N is a propri ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Development of a high-throughput assay for measuring m6A demethylase activity
SBC: Base5 Biosciences Inc Topic: NIDADESCRIPTION provided by applicant N methyladenosine m A was recently discovered to be a widespread base modification present in thousands of mammalian mRNAs In addition to its prevalence throughout the transcriptome researchers have also revealed that m A is a reversible modification suggesting that dynamic regulation of mRNA methylation is a novel and widespread RNA regulatory mechanism ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Technology-Guided Opioid Cessation for Post-Operative Pain
SBC: MedicaSafe Inc Topic: R41DESCRIPTION provided by applicant This STTR application proposes development of MedicaSafe Inc andapos s Multimodal Analgesic Protection System MAPSafe Built around MedicaSafeandapos s proprietary Medication Therapy Optimization MTO technology MAPSafe will be designed to mitigate the myriad risks associated with prescription opioid use post operatively and throughout recovery after surge ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Biological treatment of bacterial keratitis
SBC: AMEBAGONE, INC. Topic: NDESCRIPTION provided by applicant Staphylococcus is the most common cause of infections worldwide The pathogen persists asymptomatically on human skin from which it may spread to ocular tissues and cause corneal infection When this happens corneal bacterial keratitis can occur and if not treated effectively it may lead to blindness Multi Drug Resistant MDR variants of S aureus Sa are ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health